Financial Results for the quarter ended June 30, 2026

Ref: ADL/SE/2026-27/27 July 31, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sub: Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026. This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Friday, July 31, 2026, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026, in this regards we enclose:- i. Statement showing the Financial Results (Standalone and Consolidated), ii. Auditor’s Report on the Financial Results (Standalone and Consolidated), Further, please note that the Company has already made necessary arrangement to publish the financial results in the Newspapers as required under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Meeting of the Board of Directors commenced at 2:30 PM and concluded at 5:20 PM. Kindly take the same on record. Thanking you Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Il= Tet.:022-2407 2249 I 24Ol 9025 (30 Lines) Aarti Drugs Limited Fax.:022-2407 3462 I 2407 Ol44 Email : admin@aartidrugs.com website : www.aaftidrugs.com Manufacturerc of : Bulk Drugs & Chemicals CIN No. : til7060MH 1984P1C055433 AARTI ORUGS LIMITEO TEMENT OF AUOITEO FINANCIAL RESULTS FOR THE ? in lakhs except for E Standalone Quarter Ended Year Ended 3r. Particulars 31st lvltr 2026 {d (AuditedI I 62,745 63,1 68 52,096 2,26,039 il Other income R? 1q ,(o lil Total lncome(l+ll 53 251 5? , ?6 Expenses : (a) Cost of materials consumed 43,456 39,929 33,381 1 ,40,185 (b) Purchase of stock-inlrade 1,245 1,212 1 ,121 4.551 (c) Changes in inventories of fintshed goods, (5,766 (5s3) (1,265, 662 work-in-progress and stock-in-trade (d) Employee benefits expense 2,6U 2,321 2.329 9,627 (e) Finance costs 695 659 682 2,638 (f) Depreciation and amortisation expense 1,521 1 ,495 1 .22.',/ 5,564 (g) Other expenses 11 ORE 1a 111 1 0.1 34 44,940 Total expenses (lvl 47 2,08,167 Profit before exceptional items and tax (lll - lV) 6,994 5,856 4,525 18,'131 Exceptional items ?o9 vil 6,785 5,856 4,525 18,1 31 vilr Tax Expenses Provision for taxation - Current '1,600 1 500 950 3.850 - Earlier year (1 .489 \3 12 t" Provision for deferred taxatron 100 (140) 2.OO 485 Total tax expenses (Vilt) 1,700 1 360 (339 1 ,208 IX / (Loss) for the Year ( Vll - Vlll ) 5,085 4,496 4,864 16,922 X Comprehensive lncome that will not to be reclasslfied to statement of Profit and Loss value changes on lnvestmenls, 334 334 (s3) currency translation reserve tax relating to items that will not be reclassified to profit or loss air value changes on lnvestments, (48 (48) Remeasuremenl of defined benefit Liabiliy/Assets, 13 13 Total Other Comprehensive lncom6,net 247 247 XI otal Comprehensive lncome for the Year (lX+X) u,otu 4,743 o,uao 1 7,1 69 xI average number of equtty shares used for computing earntng per share (face value of Rs 10 each) 9,127 9,127 9,127 9,127 Profit attributable to l Cwner of the Company 5 085 4.496 4,864 16,922. Non- Controlling lnterest Total Comprehensive lncome attributable to Owner of the Company 5 085 4 743 4 864 r/ 169 Non- Controlling lnterest Earning per,gqgity share ( in Rs.) (not annualised) -.i.ea s.5r 18.54 A.e3 5.33 1A Noles 1' fhe above results for the Quarter ended 30th June, 2026 haue been reviewed by the Audit Commitlee and approved by the Board of Directors tn thetr meettng held on 31 st Juiy, 2026. ? Exceptional item represents the wrlte-otf of Capital Work-in-Progress (CWIP) of Rs.2.09 Cr. pertaining to the admrnistrative building situated ar E1, as an ' routine expansion plans Company has only one business segment i.e. pharmaceuticals. 4 Statutory Auditors have canied out audit of the above financlal results for the quarter ended 30th June,2o26 and have expressed unmodified audit opinion 5 Figures for the previous Quarter have been regrouped or rearranged wherever necessary. ^" Ihe aforesaid Audited Frnancial Results will be uploaded on the Company's website www.aartidrugs com and will also be available on the website of USE: t,lmrted www bserndra com and the National Stock Exchange ol lndia Limited www nserndra com for the benefit of the shareholders and tnvestors Place lvlumbai Date 31st July.2026 DrN 00005618 Regd. Office : Plot No, N-198, MIDC, Tarapur, Tal-Palghar, Dist.Palghar - 401 506.(MH) Corporate Office : Mahendra Industrial Estate, f: iD Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: O22-2407 2249 I 240t 9025 (30 Lines) Aarti Drugs Limited Fax; 022-2407 3462 I 2407 OL44 Email : admin@aartidrugs.com website: www.aartidrugs.com Manufacturers of : Bulk Drugs & Chemicals CIN No. : Ul7060MH 1984P1C055433 AARTI DRUGS LIMITED 5 I A I tsMEN I OF AUL'ITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE' 2026 ( ? in lakh_:_except_for. I Revenue from operations 70,278 72,030 59,051 2,56,53 1 lr Other income R1 7A 11 ,10 ilt Total lncome(l+ll ) 72 59.082 2.56.770 Expenses l (a) Cost of materials consumed 46,935 42.719 35 725 1,50,401 (b) Purchase of stock-in{rade 2,138 2,961 11 508 (c) Changes in inventories of finished goods, (6,3131 (1,009' (1,247 (37 work-in-progress and stock-in{rade (d) Employee benefits expense 3,651 3,228 12,932 (e) Frnance costs 922 816 3,371 (f) Deprecratron and amortrsatron expense 1,846 1,804 6,697 (g) Other expenses ,IA n,A7 14,1 80 _11,224 50,80 / Total expenses (lV) A6 070 _ _ __i!,9t1 --- 235,680 before exceptional items and tax (lll - lV) 7,,t32 7,036 5,11 1 6,924 7,036 5,111 vilt ax Expenses Provision for taxation - Current 1 ,806 1.768 1,035 - Earlier year Provision for deferred taxation '105 (258 Total tax expenses (Vlll) 1,911 '1 510 X Profit / (Loss) for the Year ( Vll - Vlll ) 5,013 5,526 Other Comprehensive lncome Item that will not to be reclassified to statement of Profit and Loss Fair value changes on lnvestments, 334 Remeasurement of defined benefit Liabtliy/Assets, (32. Foreign currency translation reserve b I 11 lncome tax relating to items that will not be reclassified to profit or loss Fair value changes on lnvestments, (48, (48) Remeasurement of defined benefit Liabiliy/Assets, : 13 13 ( Total Other Comprehensive lncome,net 6 277 11 320 Total Comprehensive lncome for the Year (lX+X) 5,019 5,803 5,408 19,814 (ll average number of equity shares used for computtng earntng per share (face value of Rs.10 each) 9,127 9,127 9,127 9,127 Profit attributable to 5,017 5,519 5,391 ta ao) 655 624 203 'T'otal Comprehensive lncome attributable to 5,023 5,796 5.402 19 809 (ll (4) '7 02 6 81 463 -----:: 5. ?1 1R Notes The above results for the Quarter ended 30th June, 2026 have been revlewed by the Audit Commlttee and approved by the Board of Drrectors in their 1 meeting held on 31st July, 2026 As on June 30,2026 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limtted, Aarti Speciality Chemrcals Limited, pinnacle Chile SpA and 2 (two) step down subsidiary, namely Pharma Go SpA., Tripharma Chite SpA. Exceptional item represents the write-off of Capital Work-in-Progress (CWIP) of Rs.2.09 Cr. pertaining to the administrative building situated at E1. as an 3 routine expansion plans 4 Company has only one business segment i.e. pharmaceuticals. Statutory Auditors have carried out audit of the above financial results for the quarter ended 3oth June,2026 and have expressed unmodifi [Showing first 8,000 characters — download PDF for full document]